Clinical and economic burden of postoperative nausea and vomiting : Analysis of existing cost data
Copyright © 2020 Elsevier Ltd. All rights reserved..
Postoperative nausea and vomiting (PONV) is an undesirable outcome that occurs in up to 30% of patients. Over the years, the cost of treating PONV has decreased due to the availability of cheaper yet effective antiemetics. Limiting PONV development benefits the hospital system as studies have shown that prevention is associated with shorter post-anesthesia care unit (PACU) stays as well as decreased supply costs and staffing burden. The financial burden for prophylaxis against PONV has been shown to be less than what patients are willing to pay to prevent the development of PONV. Studies have also shown that prevention of initial development of PONV limits readmission rates, which is beneficial to both the patient and the hospital. Owing to recent economic analysis and reductions in antiemetic prices, the patient's preference for comfort, the hospital's commitment to providing the best care, and the system's desire for fiscal prudence are aligned. This culminates in recommending PONV prophylaxis for all patients undergoing anesthesia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Best practice & research. Clinical anaesthesiology - 34(2020), 4 vom: 08. Dez., Seite 681-686 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gress, Kyle [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiemetics |
|---|
| Anmerkungen: |
Date Completed 01.06.2021 Date Revised 01.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bpa.2020.07.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318538075 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318538075 | ||
| 003 | DE-627 | ||
| 005 | 20231225165546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bpa.2020.07.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM318538075 | ||
| 035 | |a (NLM)33288118 | ||
| 035 | |a (PII)S1521-6896(20)30058-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gress, Kyle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and economic burden of postoperative nausea and vomiting |b Analysis of existing cost data |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2021 | ||
| 500 | |a Date Revised 01.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Postoperative nausea and vomiting (PONV) is an undesirable outcome that occurs in up to 30% of patients. Over the years, the cost of treating PONV has decreased due to the availability of cheaper yet effective antiemetics. Limiting PONV development benefits the hospital system as studies have shown that prevention is associated with shorter post-anesthesia care unit (PACU) stays as well as decreased supply costs and staffing burden. The financial burden for prophylaxis against PONV has been shown to be less than what patients are willing to pay to prevent the development of PONV. Studies have also shown that prevention of initial development of PONV limits readmission rates, which is beneficial to both the patient and the hospital. Owing to recent economic analysis and reductions in antiemetic prices, the patient's preference for comfort, the hospital's commitment to providing the best care, and the system's desire for fiscal prudence are aligned. This culminates in recommending PONV prophylaxis for all patients undergoing anesthesia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a PONV | |
| 650 | 4 | |a costs | |
| 650 | 4 | |a economics | |
| 650 | 4 | |a nausea | |
| 650 | 4 | |a outcomes | |
| 650 | 4 | |a vomiting | |
| 650 | 7 | |a Antiemetics |2 NLM | |
| 700 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Urman, Richard D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Best practice & research. Clinical anaesthesiology |d 2002 |g 34(2020), 4 vom: 08. Dez., Seite 681-686 |w (DE-627)NLM122752538 |x 1878-1608 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:4 |g day:08 |g month:12 |g pages:681-686 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bpa.2020.07.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2020 |e 4 |b 08 |c 12 |h 681-686 | ||